“通脉口服液”延缓肾小管间质纤维化研究

Study on mechanism of Tongmai oral liquid delaying tubule-interetiti al fibrosis(TIF)

在前期实验结果表明益气活血中药复方"通脉口服液"对UUO致肾小管间质纤维化模型大鼠良好药效的前提下,探讨其疗效机制.通过免疫组化法检测肾组织内colIV、MMP-9、TIMP-1的蛋白表达,原位分子杂交方法检测肾组织结缔组织生长因子CTGFmRNA的表达,E lisa法检测肾组织及血清t-PA、PAI的含量.结果显示,"通脉口服液"可明显下调colIV的表达;"通脉口服液"可明显上调MMP-9并下调TIMP-1的表达;"通脉口服液"可明显降低CTGFmRNA的表达;"通脉口服液"可明显升高肾组织内t-PA,降低肾组织PAI的含量,但对血清内t-PA、PAI含量无影响.

On the basis of the better pharmacodynamics function on UUO model rats,this paper try to approach the mechanism of the function.Observes the express of colIV,MMP-9 and TIMP-1 through the method of immunohistochemistry and the express of CTGFmRNA through the method of molecular hybridization.Observes the content of t-PA and PAI in the kidney and blood serum.Tongmai oral liquid can greatly down regulate the express of colIV.Tongmai oral liquid can greatly up regulate the express of MMP-9 and down regulate the express of TIMP-1.Tongmai oral liquid can greatly up regulate the content of t-PA and down regulate the content of PAI in the kidney while have no effect to that in the blood serum.